Isofagomine tartrate

Drug Profile

Isofagomine tartrate

Alternative Names: afegostat tartrate; AT 2101; HGT-3410; isofagomine-ERT combo therapy; Plicera; Plicera-ERT combo therapy

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk; University of Maryland, Baltimore
  • Developer Amicus Therapeutics
  • Class Antihyperglycaemics; Imino pyranoses; Pharmacological chaperones; Piperidines; Small molecules
  • Mechanism of Action Glucosylceramidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I

Highest Development Phases

  • No development reported Gaucher's disease type I
  • Discontinued Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gaucher's disease type I(Combination therapy) in USA (PO, Capsule)
  • 15 Dec 2016 Biomarkers information updated
  • 28 Feb 2012 Isofagomine tartrate is still in preclinical trials for Gaucher's disease (combination therapy) in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top